chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Received 2 injections. Flu on (R) thigh on Wednesday afternoon. Thursday noticed rash on (R) leg. Fever Sat. Rash had spread to chest & abdomen on (R) side. ZITHROMAX for ears. PREVNAR on (L) thigh. ORAPRED 15mg/5mL 1/2 teaspoon qd x5.
The adverse event started two months after taken the vaccine, which started in  early December with ringing in the left ear which renonsance to my left brain. This is a non-stop ringing.
Fever 102 F; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (Fever 102 F) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No reported medical history).    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 29-Dec-2020, the patient experienced PYREXIA (Fever 102 F). At the time of the report, PYREXIA (Fever 102 F) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 29-Dec-2021, Body temperature: 102 f (Inconclusive) 102 F.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Based on the established safety profile and a temporal association between the reported events and administration of mRNA-1273 vaccine, a causal association cannot be excluded. Pyrexia is consistent with the known safety profile of the vaccine.; Reporter's Comments: Based on the established safety profile and a temporal association between the reported events and administration of mRNA-1273 vaccine, a causal association cannot be excluded. Pyrexia is consistent with the known safety profile of the vaccine.
Fever, body aches, chills, headaches, achy skin, swelling at injection sight, redness at injection site.
PATIENT HAD FEVER AND FATIGUE FOLLOWING THE ADMINISTRATION OF H1N1 VACCINE.
At or around 2300 on 2/4/2021 I began feeling tense, major body aches, and had a temp of 99.6°. I went to emergency department for nausea vomiting. Dizziness. Seeing stars when moving, and  rapid heart beat that would not stop and my chest began hurting.  Dr saw me in the Ed where I was administered iv bolus fluids along with the meds: toradol, dexamethasone, pepsid, Benadryl, and zofran.  I went home and laid on the couch all evening until the chest pain became so intense I went to new medical center emergency department. I was then given iv fluids along with phenergan, toradol, dilaudid, and Ativan. I got a chest X-ray, ecg, ekg, and a bunch of blood work to rule out things.
vaccination site pain; Cough; rash over arms; This spontaneous case was reported by a physician and describes the occurrence of COUGH (Cough), RASH (rash over arms) and VACCINATION SITE PAIN (vaccination site pain) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 027A21A and 003B21A) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Arthritis rheumatoid.    no specified medical history was reported.  Concomitant products included LOSARTAN for Blood pressure, ACETYLSALICYLIC ACID (BABY ASPIRIN) for Heart disorder, METHOTREXATE and FOLIC ACID for Rheumatoid arthritis, MULTIVITAMIN [ASCORBIC ACID;CALCIUM PANTOTHENATE;COLECALCIFEROL;CYANOCOBALAMIN;NICOTINAMIDE;PYRIDOXINE HYDROCHLORIDE;RETINOL;RIBOFLAVIN;THIAMINE HYDROCHLORIDE;TOCOPHERYL ACETATE], VITAMIN D3 and VITAMIN B12 NOS (VITAMIN B 12 [VITAMIN B12 NOS]) for Supplementation therapy.   In 2004, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) 40 mg. On 04-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 14-Mar-2021, the patient experienced RASH (rash over arms). On 15-Apr-2021, the patient experienced COUGH (Cough). On an unknown date, the patient experienced VACCINATION SITE PAIN (vaccination site pain). On 18-Mar-2021, RASH (rash over arms) had resolved. On 15-Apr-2021, COUGH (Cough) had resolved. At the time of the report, VACCINATION SITE PAIN (vaccination site pain) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter considered COUGH (Cough) and RASH (rash over arms) to be probably related. No further causality assessment was provided for VACCINATION SITE PAIN (vaccination site pain).    No treatment medication were reported.   This case was linked to MOD-2021-097090 (Patient Link).
Acute hives - urticaria. Currently taking Allegra, Pecid AC and steroids for 6 days now.  Hives come back when meds wear off. Also using Calamine lotion for quick relief .
Nausea; Headache; Fatigue started about 5 hours after injection and seems to be getting worse; Muscle aches-started about 5 hours after injection and seems to be getting worse; Stiff Arm; Slight pain at injection site; This is a spontaneous report from a contactable nurse, the patient.  A 44-years-old female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EJ1685), via an unspecified route of administration, in the right arm on 30Dec2020 at 06:45 AM (at the age of 44-year-old) as a single dose for COVID-19 immunization. Medical history included crohn's disease, ankylosing spondylitis, gastroparesis, and sulfa allergy. The patient was not pregnant at the time of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medication taken within two weeks of vaccination were not reported. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 30Dec2020 at 07:45 AM, about an hour after injection, the patient experience nausea and headache. Fatigue and muscle aches started about 5 hours after injection and seemed to be getting worse. The patient experienced stiff arm 12 hours after injection, and slight pain at injection site after 12 hours. The events were reported as non-serious. The patient did not receive any treatment for the nausea, headache, fatigue, muscle aches, stiff arm, and slight pain at injection site. The clinical outcome of the events nausea, headache, fatigue, muscle aches, stiff arm, and slight pain at injection site was recovering. It was also reported that since the vaccination, the patient had not been tested for COVID-19.
day p/vax pt states went to ER-redness-swelling-near elbow to inside arm placed on ATB;this was 2nd pneumovax <10yr apart;
This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 07-Mar-2022) and PRODUCT STORAGE ERROR (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 07-Mar-2022) in a 21-year-old female patient who received mRNA-1273 (Spikevax) (batch no. 066H21A) for COVID-19 vaccination. No Medical History information was reported. On 07-Mar-2022 at 11:24 AM, the patient received first dose of mRNA-1273 (Spikevax) (unknown route) .5 milliliter. On 07-Mar-2022 at 11:24 AM, the patient experienced EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 07-Mar-2022). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 07-Mar-2022). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 07-Mar-2022) and PRODUCT STORAGE ERROR (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 07-Mar-2022) outcome was unknown. For mRNA-1273 (Spikevax) (Unknown), the reporter did not provide any causality assessments. No concomitant product use was reported. The patient received vaccine past its 30 days expiry date on 07-Mar-2022 at 11:24:41 AM. Vaccine went into 2 to 8 degree Celsius thaw state on about 24-Dec-2021. The vaccine was administered up until its manufacturing expiry date of 04-Apr-2022. No treatment information was provided.
Low grade fever, chills, pretty bad muscle aches, terrible sleep, dizzy, skin warm to the touch
red swelling around the area and has been feeling pretty warm; red swelling around the area and has been feeling pretty warm and itchy; red swelling around the area; was sore for two days; This spontaneous case was reported by a patient and describes the occurrence of VACCINATION SITE WARMTH (red swelling around the area and has been feeling pretty warm), PAIN (was sore for two days), VACCINATION SITE PRURITUS (red swelling around the area and has been feeling pretty warm and itchy) and VACCINATION SITE ERYTHEMA (red swelling around the area) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 07-Jan-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 07-Jan-2021, the patient experienced PAIN (was sore for two days). On 14-Jan-2021, the patient experienced VACCINATION SITE WARMTH (red swelling around the area and has been feeling pretty warm), VACCINATION SITE PRURITUS (red swelling around the area and has been feeling pretty warm and itchy) and VACCINATION SITE ERYTHEMA (red swelling around the area). On 08-Jan-2021, PAIN (was sore for two days) had resolved. At the time of the report, VACCINATION SITE WARMTH (red swelling around the area and has been feeling pretty warm), VACCINATION SITE PRURITUS (red swelling around the area and has been feeling pretty warm and itchy) and VACCINATION SITE ERYTHEMA (red swelling around the area) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported. The patient stated that red swelling area grew to a larger area on her arm. No treatment information was provided.
2/6 Vaccination 5 hours later, red, rash spread on arm 3-4" height and 5" across.  Three weeks later, I started noticing soreness under my arm, going into my right breast . The breast was feeling enlarged and sore all the way around. The Dr said this is affecting lymph nodes and to hold off on having mammogram.
Persistent pain in left arm since the injection - Pain in upper arm and shoulder with raising arm to reach for items. Recommended patient to physical therapy for treatment.
This spontaneous report as received from a other health professional refers to a 11 year old male patient. The patient did not have any pertinent medical history or drug reactions/allergies. On 21-JUL-2014, the patient was vaccinated with a first dose of GARDASIL (lot # J009243, expiration date 23-APR-2016) 0.5 ml, intramuscular for immunization along with MENVEO, DTaP vaccine (unspecified), TdaP and hepatitis a vaccine (manufacturer unknown). On 21-JUL-2014, immediately after the GARDASIL was administered, the patient's head rolled back and his eyes rolled back in his head. She stated that he experienced a "vaso vagal event". The patient was sitting during the injection and did not have any injury. The patient "came back to" shortly after and reported feeling lethargic. No treatment was given. No lab diagnostic studies were performed. On 21-JUL-2014, the patient recovered from the events. Additional information has been requested.
Sore injection site, 102 fever, chills, diarrhea, vomiting. Most symptoms ended by 4/23.  Lingering diarrhea.
Information has been received on 11/20/2001 from a physician ocncerning a 12 month old female who "two months ago" was vaccinated with a dose of varicella vaccine. On 09/13/2001, the child developed a papular rash from the left shoulder to elbow and from hip to left knee. It was reported that there was no improvement with the use of calamine lotion and Benadryl. On 01/04/2002, the reporter indicated that she did not know who the pt was. No further info is expected.
elevated Liver Function; This case was reported by a physician via call center representative and described the occurrence of elevated liver enzymes in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix at an unknown dose. On an unknown date, unknown after receiving Shingrix, the patient experienced elevated liver enzymes. On an unknown date, the outcome of the elevated liver enzymes was unknown.   It was unknown if the reporter considered the elevated liver enzymes to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The physician reported an elevated Liver Function Test after a patient received Shingrix. The follow up consent was not granted.      Lab Comments: Lab test performed on an unknown date
Pt was leaving facility, began having dizziness, and had sycopal episide causing him to fall and hit head on floor. Sent to ED via PV for possible concussion. CT scan normal.
Hospitalization: 8/26/2022 ADMITTED 9/9/2022 DISCHARGED. Presentation to the ED: nausea, vomiting, shortness of breath.  COVID-19 + date: 8/26/22. Treatment: WAS NOT GIVEN REMDESIVIR D/T TESTING POSITIVE FOR MORE THAN 2 WEEKS. PATIENT WAS PREVIOUSLY POSITIVE FOR COVID ON 8/11/22 AND WAS ALSO ADMITTED TO THE HOSPITAL THEN. Discharge to: HOME.
Five days after admin. of Flu Vaccine, I very suddenly developed extreme joint pain in my knee (was nearly unable to walk up stairs), which lasted 3 days, and then disappeared over-night.  Pain then developed in my shoulder joint.  It continues, though it seems to be very gradually improving.  My grandson has had a very similar event:  He is 3 years old and developed over-night(two days after the vaccine injection)such extreme pain in his leg/knee joint that he could/would not walk on his leg.  He also had arm pain, though not as extreme.  Because this had happened to me, my daughter waited to take him to the pediatritian.  However, it did not resolve, and after six days, he did see the MD.  She evaluated/drew labs, etc, and stated their practice had seen two other children with the same events.  One who actually was hospitalized.  Once again...overnight the pain disappeared, however it has now moved to his other leg, though it is less severe.  His pediatritian stated she felt it was probably a reaction to the thimerosol in the vaccine, and that he should never have another flu shot.
Sore throat; Runny nose; Sore Arm; A little rash around the shot; Shoulders ached; Fever; Cold Chills; This spontaneous case was reported by a consumer and describes the occurrence of OROPHARYNGEAL PAIN (Sore throat), RHINORRHOEA (Runny nose), VACCINATION SITE PAIN (Sore Arm), VACCINATION SITE RASH (A little rash around the shot) and ARTHRALGIA (Shoulders ached) in a 58-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037K20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history was provided by the reporter.     On 29-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1. On an unknown date, the patient experienced OROPHARYNGEAL PAIN (Sore throat), RHINORRHOEA (Runny nose), VACCINATION SITE PAIN (Sore Arm), VACCINATION SITE RASH (A little rash around the shot), ARTHRALGIA (Shoulders ached), PYREXIA (Fever) and CHILLS (Cold Chills). At the time of the report, OROPHARYNGEAL PAIN (Sore throat), RHINORRHOEA (Runny nose), ARTHRALGIA (Shoulders ached), PYREXIA (Fever) and CHILLS (Cold Chills) outcome was unknown and VACCINATION SITE PAIN (Sore Arm) and VACCINATION SITE RASH (A little rash around the shot) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were provided. No treatment information provided.
Vaccinator Nurse noted upon vaccination there was bleeding from site and immediate bruising. Extended post vaccination monitoring to 30 minutes and asked patient to not leave before being reevaluated. Visual monitoring in post vaccination space by this RN.    Upon reassessment @ 1352 pt stated she felt the need to use her inhaler and chest tightness. Pt denies SOB and able to transfer independently to wheelchair. Pt began to cough and was immediately transferred to ED per FNP.      Upon ED arrival, pt was transferred to back hall 9, report given to RN and assessed by physician. Vital signs 98% on RA, t- 98.2, HR 78.
I received my Covid 19 vaccine on 07/16/2022. On 07/29/2022 I started having a running noise. 07/30/2022 I woke up with lots of congestion and mucus. I felt achy and tired and lots of mucus with a stuffy head. On 07/31/2022 I went to the doctor and was diagnosed with Covid-19. I was prescribed PAXLOVID for 3x for 5 days. Symptoms gradually improved from next day and completely went away day 6.
Hives, itching. Joint pain. Weakness, Fever. Sore throat.
received dose from vial that had black particulates in previous syringe; This spontaneous case was reported by a pharmacist and describes the occurrence of PRODUCT QUALITY ISSUE (received dose from vial that had black particulates in previous syringe) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012H21B) for COVID-19 vaccination.     No Medical History information was reported.    On 01-Dec-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 01-Dec-2021, the patient experienced PRODUCT QUALITY ISSUE (received dose from vial that had black particulates in previous syringe). On 01-Dec-2021, PRODUCT QUALITY ISSUE (received dose from vial that had black particulates in previous syringe) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter.   Treatment information was not provided.
I21.4 ACUTE NON ST ELEVATION MI 5/8/2021 ASTEATOSIS CUTIS J96.21 ACUTE ON CHRONIC HYPOXEMIC RESPIRATORY FAILURE 5/8/2021 ASTEATOSIS CUTIS I21.4 ACUTE NON ST ELEVATION MI 5/8/2021 DIASTOLIC HEART FAILURE, CHRONIC J96.21 ACUTE ON CHRONIC HYPOXEMIC RESPIRATORY FAILURE 5/8/2021 DIASTOLIC HEART FAILURE, CHRONIC
Vaccine was used for doses after expired date; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Vaccine was used for doses after expired date) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039D21A) for COVID-19 vaccination.     No Medical History information was reported.    On 12-Oct-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 12-Oct-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Vaccine was used for doses after expired date). On 12-Oct-2021, EXPIRED PRODUCT ADMINISTERED (Vaccine was used for doses after expired date) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No Concomitants and Treatment medication were reported.   This case was linked to MOD-2021-359475 (Patient Link).
today feeling headaches; fatigue; dizziness; 2nd lethargic; dose number=1/administration date=11Jan2021/other vaccine same date product= Pfizer, other vaccine same date vaccine date=29Jan2021,other vaccine same date dose number=2; dose number=1/administration date=11Jan2021/other vaccine same date product= Pfizer, other vaccine same date vaccine date=29Jan2021,other vaccine same date dose number=2; sleepy on the first day; This is a spontaneous report from a contactable consumer (patient). A 80-year-old non-pregnant female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Formulation: Solution for injection Batch/Lot number was not reported, Expiration Date was not reported), via an unspecified route of administration on 29Jan2021 (at the age of 80-year-old) as 2nd dose, single dose for covid-19 immunisation. The patient medical history included tobacco(Smoker). Concomitant medications were not reported. The patient previously took buspar. Other medication in two weeks included Buspar. The patient historical vaccine included first dose of BNT162B2 for COVID-19 immunization received on 11Jan2021 13:00. No other vaccine was received in four weeks. Patient had not been diagnosed with COVID-19 prior to vaccination and had not tested positive since the vaccination. On 29Jan2021 the patient experienced sleepy on the first day, 2nd lethargic, 3rd ok and 4th day, today feeling headaches fatigue and dizziness. No treatment received for AE. The outcome of the events sleepy, lethargic, headaches, fatigue, dizziness was reported as not recovered and unknown for other events.  Information on batch/lot number was requested.  Follow-up (26May2021): This follow-up is being submitted to notify that the lot/batch number is not available despite the follow-up attempts made. Follow-up attempts have been completed and no further information is expected
fever up to 102.2 and severe joint pain to the point of pain upon touch and difficulty walking due to joint pain.
Information has been received from a registered nurse concerning a 26 year old female with a history of colitis who on 16-ARPR-2007 was vaccinated IM with the first dose of Gardasil (lot # 657621/0387U). On 19-JUN-2007 was vaccinated IM with the second dose of Gardasil (lot # 0211U). Concomitant therapy included FEMCON FE. Immediately after the second dose the patient experienced "extreme lightheadedness and dizziness". Unspecified medical attention was sought. The registered nurse reported the symptoms lasted "within 10 minutes or so". On 19-JUN-2007, the patient recovered from "extreme lightheadedness and dizziness". There were no laboratory or diagnostic tests performed. It was reported that the patient did not experience any symptoms after receipt of the first dose. Additional information has been requested. This is in follow-up to report(s) previously submitted on 7/16/2007.  Initial and follow-up information has been received from a registered nurse concerning a 26 year old female with a history of colitis who on 16-APR-2007 was vaccinated IM with the first dose of GARDASIL (lot # 657621/0387U).  On 19-JUN-2007 was vaccinated IM with the second dose of GARDASIL (lot # 0212U).  Concomitant therapy included FEMCON FE.  Immediately after the second the patient experienced "extreme lightheadedness and dizziness".  Unspecified medical attention was sought.  The registered nurse reported the symptoms lasted "within 10 minutes or so".  On 19-JUN-2007, the patient recovered from "extreme lightheadedness and dizziness".  There were no laboratory or diagnostic tests performed.  It was reported that the patient did not experience any symptoms after receipt of the first dose.  Additional information is not expected.
Shot administered to left deltoid.  Muscle cramping similar to muscle fatigue in upper arms and lower legs (pain scale 1).  Severe muscle cramping of abdomen (7 on pain scale) starting in evening.  Subsided after naproxin 500mg administered and hot bath.